MCID: ACT020
MIFTS: 54

Acute T Cell Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acute T Cell Leukemia

MalaCards integrated aliases for Acute T Cell Leukemia:

Name: Acute T Cell Leukemia 12 15
T-Cell Acute Lymphoblastic Leukemia 12 29 6
Leukemia, Acute T-Cell 13 40
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 73
Precursor T-Cell Lymphoblastic Lymphoma 73
Precursor T Lymphoblastic Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
ICD10 33 C91.5 C91.50
MeSH 44 D015459
NCIt 50 C3184
SNOMED-CT 68 77430005

Summaries for Acute T Cell Leukemia

MalaCards based summary : Acute T Cell Leukemia, also known as t-cell acute lymphoblastic leukemia, is related to precursor t-cell acute lymphoblastic leukemia and acute lymphocytic leukemia. An important gene associated with Acute T Cell Leukemia is BCL10 (BCL10, Immune Signaling Adaptor), and among its related pathways/superpathways are NF-kappaB Signaling and Transcriptional misregulation in cancer. The drugs Bupivacaine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Acute T Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Acute T Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 precursor t-cell acute lymphoblastic leukemia 33.0 BAX BCL10 CD7 FBXW7 LMO1 LMO2
2 acute lymphocytic leukemia 31.4 NOTCH1 TAL1 TLX3
3 leukemia, acute myeloid 30.6 CASP8 CD7 CXCL12 MTOR NUP214
4 lymphoblastic lymphoma 30.3 NOTCH1 TAL1 TRB
5 t-cell leukemia 30.1 BCL11B CD7 LMO1 LMO2 NOTCH1 TAL1
6 lymphoma 30.0 BAX BCL10 BCL11B TCL6
7 leukemia, chronic lymphocytic 30.0 BAX BCL10 CASP8 CXCL12 NOTCH1
8 lymphoma, non-hodgkin, familial 29.9 BAX BCL10 CASP8 CD7 CXCL12 NOTCH1
9 leukemia, acute lymphoblastic 12.3
10 t-cell adult acute lymphocytic leukemia 11.5
11 leukemia 10.5
12 myeloid leukemia 10.4
13 hematopoietic stem cell transplantation 10.4
14 glucocorticoid resistance, generalized 10.3
15 xp22.3 microdeletion syndrome 10.2
16 ataxia-telangiectasia 10.2
17 fanconi anemia, complementation group a 10.2
18 langerhans cell histiocytosis 10.2
19 acute promyelocytic leukemia 10.2
20 wilms tumor 6 10.2
21 interleukin-7 receptor alpha deficiency 10.2
22 thrombosis 10.2
23 hemopericardium 10.2
24 pericardial effusion 10.2
25 pure red-cell aplasia 10.2
26 thymoma 10.2
27 histiocytosis 10.2
28 pancreatitis 10.2
29 paraplegia 10.2
30 sezary's disease 10.1 BCL10 CD7 TRB
31 testicular germ cell tumor 10.1 BCL10 HSD17B1 PTEN
32 lymphocytic leukemia 10.1
33 oral cavity cancer 10.1 BAX CASP8 PTEN
34 breast adenocarcinoma 10.1 BAX CASP8 PTEN
35 hematologic cancer 10.0 BAX CD7 CXCL12 MTOR NOTCH1
36 cervical cancer 10.0 BAX CASP8 MTOR NOTCH1 PTEN
37 leukemia, chronic lymphocytic 2 10.0
38 medulloblastoma 10.0
39 thrombophilia due to thrombin defect 10.0
40 wilms tumor 1 10.0
41 lymphoma, hodgkin, classic 10.0
42 myasthenia gravis 10.0
43 neuroblastoma 10.0
44 ocular motor apraxia 10.0
45 juvenile myelomonocytic leukemia 10.0
46 leukemia, chronic myeloid 10.0
47 aplastic anemia 10.0
48 aspergillosis 10.0
49 myelodysplastic syndrome 10.0
50 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0

Graphical network of the top 20 diseases related to Acute T Cell Leukemia:



Diseases related to Acute T Cell Leukemia

Symptoms & Phenotypes for Acute T Cell Leukemia

GenomeRNAi Phenotypes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 BCL11B CD7 LMO2 MTOR NOTCH1 NUP214

MGI Mouse Phenotypes related to Acute T Cell Leukemia:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 BAX BCL10 BCL11B CASP8 CXCL12 FBXW7
2 immune system MP:0005387 10.22 BAX BCL10 BCL11B CASP8 CD7 CXCL12
3 hematopoietic system MP:0005397 10.21 BAX BCL10 BCL11B CASP8 CD7 CXCL12
4 mortality/aging MP:0010768 10.2 BAX BCL10 BCL11B CASP8 CXCL12 FBXW7
5 endocrine/exocrine gland MP:0005379 10.16 BAX BCL10 BCL11B CASP8 CD7 FBXW7
6 embryo MP:0005380 10.13 BCL10 CASP8 FBXW7 LMO2 MTOR NOTCH1
7 integument MP:0010771 9.97 BCL11B CASP8 FBXW7 LMO2 NOTCH1 PTEN
8 nervous system MP:0003631 9.9 BAX BCL10 CASP8 CXCL12 FBXW7 LMO2
9 neoplasm MP:0002006 9.86 BAX BCL11B CASP8 FBXW7 LMO2 NOTCH1
10 renal/urinary system MP:0005367 9.5 BAX CASP8 LMO2 MTOR NOTCH1 PTEN
11 respiratory system MP:0005388 9.17 BAX CASP8 FBXW7 MTOR NOTCH1 PTEN

Drugs & Therapeutics for Acute T Cell Leukemia

Drugs for Acute T Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 2180-92-9, 38396-39-3 2474
2
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
3
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
4
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
5 Central Nervous System Depressants Phase 4,Phase 1,Phase 2,Not Applicable
6 Mydriatics Phase 4
7 Epinephryl borate Phase 4,Not Applicable
8 Anti-Asthmatic Agents Phase 4
9 Adrenergic beta-Agonists Phase 4
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Sympathomimetics Phase 4
12 Adrenergic alpha-Agonists Phase 4
13 Adrenergic Agonists Phase 4
14 Vasoconstrictor Agents Phase 4
15 Respiratory System Agents Phase 4
16 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
17 Bronchodilator Agents Phase 4
18 Anesthetics, Local Phase 4,Phase 1,Phase 2,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Neurotransmitter Agents Phase 4,Phase 2
21 Adrenergic Agents Phase 4,Phase 2
22 Calamus Phase 4
23
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
24
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
25
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
26
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
28
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
29
Cortisone acetate Approved, Investigational Phase 3,Phase 2 1950-04-4, 50-04-4 5745
30
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
32
Daunorubicin Approved Phase 3,Phase 2,Not Applicable 20830-81-3 30323
33
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
34
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
35
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
36
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
37
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
38
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
39
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
40
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
41
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
42
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
43
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
44
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
45
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
46
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
47
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
48
Ifosfamide Approved Phase 3 3778-73-2 3690
49
Fludarabine Approved Phase 3,Phase 1 75607-67-9, 21679-14-1 30751
50
Bortezomib Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator Nerve Blockade Completed NCT03064165 Phase 4 Bupivacaine-epinephrine;Sodium Chloride 9mg/mL
2 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
3 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Recruiting NCT03781310 Phase 4 Tocilizumab
4 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
5 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
6 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
7 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
8 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
9 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
10 Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit Completed NCT02043223 Phase 2, Phase 3
11 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
12 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
13 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
14 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine
15 A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Recruiting NCT02716233 Phase 3 pegaspargase 1250 IU/m2 x 2;pegaspargase 2500 IU/m2 x 1
16 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
17 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Recruiting NCT03643276 Phase 3 Blinatumomab;Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;DAUNOrubicin Liposomal Injection [DaunoXome];Dexamethasone;Doxorubicin;Etoposide;Fludarabine Phosphate;Ifosfamide;6-Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Tioguanin;Vincristine;Vindesine;Erwinase
18 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
19 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Recruiting NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
20 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
21 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
22 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Suspended NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
23 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
24 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Completed NCT00684619 Phase 2 Nelarabine
25 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
26 Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
27 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
28 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) Completed NCT00687323 Phase 2 temozolomide
29 Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
30 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Completed NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
31 Losartan Versus Atenolol for the Treatment of Marfan Syndrome Completed NCT00593710 Phase 2 Losartan;Atenolol
32 506U78 in Treating Patients With Refractory Hematologic Cancer Completed NCT00002970 Phase 2 nelarabine;methotrexate;cytarabine;therapeutic hydrocortisone
33 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
34 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00873093 Phase 2 L-asparaginase;doxorubicin hydrochloride;therapeutic hydrocortisone;vincristine sulfate;cytarabine;prednisone;bortezomib;pegaspargase;methotrexate;etoposide phosphate;cyclophosphamide;leucovorin calcium;High Dose MTX
35 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
36 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
37 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
38 BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
39 Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Doxorubicin;Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Vincristine;Nelarabine;Mesna;6-MP;Prednisone
40 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Recruiting NCT03575325 Phase 2 CPX-351
41 Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Recruiting NCT02767934 Phase 2
42 Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia Recruiting NCT02654860 Phase 1, Phase 2 Paracetamol 3%;Placebo injection containing Saline solution 0.9%;Hyperbaric Bupivacaine HCl 0.5%
43 Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Recruiting NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
44 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
45 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
46 Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Active, not recruiting NCT02484430 Phase 2 Sapanisertib
47 SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Active, not recruiting NCT01574274 Phase 2 SC-PEG;Oncaspar
48 Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Not yet recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
49 Ruxolitinib Plus LVP in Patients With R/R ETP-ALL Not yet recruiting NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
50 TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients Terminated NCT00415909 Phase 2 Imatinib Mesylate (IM);TALL-104 cells

Search NIH Clinical Center for Acute T Cell Leukemia

Genetic Tests for Acute T Cell Leukemia

Genetic tests related to Acute T Cell Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for Acute T Cell Leukemia

MalaCards organs/tissues related to Acute T Cell Leukemia:

41
T Cells, Bone, Bone Marrow, Myeloid, B Cells, Skin, Nk Cells

Publications for Acute T Cell Leukemia

Articles related to Acute T Cell Leukemia:

(show top 50) (show all 892)
# Title Authors Year
1
The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone. ( 30551478 )
2019
2
The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia. ( 30533380 )
2019
3
Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. ( 30280491 )
2019
4
Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]. ( 29443320 )
2018
5
Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. ( 29200162 )
2018
6
Hepatic leukemia-associated macrophages exhibit a pro-inflammatory phenotype in Notch1-induced acute T cell leukemia. ( 29030004 )
2018
7
Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. ( 29278703 )
2018
8
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )
2018
9
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. ( 29949919 )
2018
10
A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. ( 29954933 )
2018
11
Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. ( 29948644 )
2018
12
In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells. ( 29966986 )
2018
13
MicroRNA expression and activity in T-cell acute lymphoblastic leukemia. ( 29435192 )
2018
14
<i>WT1</i> loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. ( 29170254 )
2018
15
PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b. ( 30023329 )
2018
16
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. ( 30552401 )
2018
17
T-cell acute lymphoblastic leukemia express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development. ( 30514801 )
2018
18
CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. ( 30460757 )
2018
19
High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia. ( 30416957 )
2018
20
NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia (T-ALL). ( 30387229 )
2018
21
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. ( 30404791 )
2018
22
Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. ( 30407885 )
2018
23
Loss of miR-146b-5p promotes T cell acute lymphoblastic leukemia migration and invasion via the IL-17A pathway. ( 30362152 )
2018
24
USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia. ( 30370059 )
2018
25
Knockdown of MAML1 inhibits proliferation and induces apoptosis of T-cell acute lymphoblastic leukemia cells through SP1-dependent inactivation of TRIM59. ( 30370525 )
2018
26
Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia. ( 30320607 )
2018
27
FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia. ( 30282797 )
2018
28
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update. ( 30249539 )
2018
29
JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia. ( 30250904 )
2018
30
CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia. ( 30266989 )
2018
31
Increased Survival due to Lower Toxicity for High Risk T-cell Acute Lymphoblastic Leukemia Patients in 2 consecutive Pediatric-Inspired PETHEMA Trials. ( 30267597 )
2018
32
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. ( 30190344 )
2018
33
Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. ( 30038221 )
2018
34
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. ( 30041662 )
2018
35
Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). ( 30067411 )
2018
36
Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. ( 30076176 )
2018
37
FOXP3 knockdown inhibits the proliferation and reduces NOTCH1 expression of T cell acute lymphoblastic leukemia cells. ( 30103821 )
2018
38
Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. ( 30107177 )
2018
39
The notch pathway promotes NF-κB activation through Asb2 in T cell acute lymphoblastic leukemia cells. ( 30116272 )
2018
40
Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia. ( 30145780 )
2018
41
STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. ( 30185437 )
2018
42
Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia. ( 30206207 )
2018
43
STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. ( 30208327 )
2018
44
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. ( 30225152 )
2018
45
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. ( 30232463 )
2018
46
Identification of Endogenous Control miRNAs for RT-qPCR in T-Cell Acute Lymphoblastic Leukemia. ( 30241379 )
2018
47
Solanine induced apoptosis and increased chemosensitivity to Adriamycin in T-cell acute lymphoblastic leukemia cells. ( 29731890 )
2018
48
RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes. ( 29733873 )
2018
49
Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. ( 29740158 )
2018
50
Downregulated miR-17, miR-29c, miR-92a and miR-214 may be related to BCL11B overexpression in T cell acute lymphoblastic leukemia. ( 29749698 )
2018

Variations for Acute T Cell Leukemia

ClinVar genetic disease variations for Acute T Cell Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511
2 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh38 Chromosome 1, 85270828: 85270828
3 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
4 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh38 Chromosome 19, 48955799: 48955799
5 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh37 Chromosome 19, 49458972: 49458978
6 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh38 Chromosome 19, 48955715: 48955721

Copy number variations for Acute T Cell Leukemia from CNVD:

7 (show top 50) (show all 91)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for Acute T Cell Leukemia

Search GEO for disease gene expression data for Acute T Cell Leukemia.

Pathways for Acute T Cell Leukemia

GO Terms for Acute T Cell Leukemia

Cellular components related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 BAX BCL10 BCL11B CASP8 FBXW7 LMO1
2 nucleoplasm GO:0005654 9.36 CASP8 FBXW7 LMO1 LMO2 MTOR NOTCH1
3 postsynaptic cytosol GO:0099524 9.16 MTOR PTEN

Biological processes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.72 BAX CASP8 CXCL12 FBXW7 NUP214
2 neuron migration GO:0001764 9.63 BAX CXCL12 TLX3
3 post-embryonic development GO:0009791 9.58 BAX BCL11B MTOR
4 cell fate specification GO:0001708 9.49 NOTCH1 TLX3
5 cardiac muscle tissue development GO:0048738 9.48 MTOR PTEN
6 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 FBXW7 PTEN
7 negative regulation of cell size GO:0045792 9.37 MTOR PTEN
8 B cell apoptotic process GO:0001783 9.26 BAX BCL10
9 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.16 BAX CASP8
10 apoptotic process involved in embryonic digit morphogenesis GO:1902263 8.96 BAX NOTCH1
11 regulation of hematopoietic stem cell differentiation GO:1902036 8.8 LMO1 LMO2 TAL1

Molecular functions related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.02 BCL10 NOTCH1 PHF6 PTEN TAL1

Sources for Acute T Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....